论文部分内容阅读
Steroids and H2 blockers are commonly used in supportive care for taxane-containing chemotherapy, but they also affect the primary metabolizer of docetaxel, cytochrome P450 3A4.This retrospective observational study was performed to better understand the effects of these compounds on docetaxel-induced skin toxicities, specifically hand-foot syndrome (HFS) and facial erythema (FE).Member institutions of the Japan Breast Cancer Research Group were invited to complete a questionnaire on the occurrence of grade 2 or higher HFS and FE among patients treated between April 2007 and March 2008 with docetaxel as an adjuvant or neoadjuvant chemotherapeutic treatment for breast cancer.We obtained data for 993 patients from 20 institutions.Twenty percent received H2 blockers and all patients received dexamethasone.Univariate and multivariate analyses revealed that H2 blockers were associated with a significantly higher incidence of both HFS and FE.The incidence of FE was sign ificantly higher for the docetaxel+cyclophosphamide (TC) regimen than for non-TC combined regimens.Dexamethasone usage did not affect the incidence of HFS or FE.The findings suggest that use of H2 blockers as premedication in breast cancer patients receiving docetaxel significantly increases the risk for both HFS and FE.